Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis

Seminars in Gastrointestinal Disease

Volumn 12, Issue 4, 2001, Pages 263-274

  Bitton, A ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

12 SULFODEHYDROABIETIC ACID; AZATHIOPRINE; BALSALAZIDE; BISMUTH CITRATE; BUDESONIDE; CYCLOSPORIN; FISH OIL; GLUCOCORTICOID; HEPARIN; HYDROCORTISONE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; LIDOCAINE; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; NICOTINE; OLSALAZINE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; PROCTITIS; PROCTOSIGMOIDITIS; QUALITY OF LIFE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; COLITIS, ULCERATIVE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MESALAMINE; PREDNISONE; PROCTOCOLITIS; SIGMOIDOSCOPY;

EID: 0034753289     PISSN: 10495118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: Prevalence and diagnostic role
2. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis
3. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis
4. Rectal aminosalicylate therapy for distal ulcerative colitis: A meta-analysis
5. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis
6. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
7. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults
8. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial
9. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis
10. Dose ranging study of mesalamine (Pentasa) enemas in the treatment of acute ulcerative proctosigmoiditis: Results of a multi-centred placebo-controlled trial
11. Putting rectal 5-aminosalicylic acid in its place: The role in distal ulcerative colitis
12. Distribution of mesalamine enemas in patients with active ulcerative colitis
13. Retrograde spreading of hydrocortisone enema in inflammatory bowel disease
14. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study
15. The Treatment of left-sided ulcerative colitis with tixocortol pivalate
16. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis
17. Sulfasalazine revisited: A meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis
18. Coated oral 5-aminosalicylic acid therapy for mild to moderately active ulcerative colitis: A randomized study
19. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine: A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial
20. Controlled trial of sulphasalazine in the treatment of ulcerative colitis
21. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis
22. Asacol vs Dipentum in the treatment of acute distal ulcerative colitis
23. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
24. Continuously infused cyclosporine at low dose is sufficient to avoid emergency colectomy in acute attacks of ulcerative colitis without the need for high-dose steroids
25. Cyclosporin for severe ulcerative colitis: A user's guide
26. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
27. Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high doses by mouth
28. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis
29. Relapse preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: A prospective, double-blind, randomized multlcenter study
30. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis
31. Short report: Comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months
32. Why do patients with ulcerative colitis relapse?
33. Microscopic activity in ulcerative colitis: What does it mean?
34. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis
35. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine
36. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis
37. Controlled trial of azathioprine in chronic ulcerative colitis
38. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
39. Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial
40. Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis
41. Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid
42. Controlled trial of 4-ASA in ulcerative colitis
43. Short-chain fatty acid topical treatment in distal ulcerative colitis
44. Treatment of left-sided ulcerative colitis with butyrate enemas: A controlled trial
45. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: A randomised, placebo controlled trial
46. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial
47. Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial
48. Transdermal nicotine for active ulcerative colitis
49. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: A pilot study
50. Treatment of the mucosa with local anaesthetics in ulcerative colitis
51. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: A controlled trial
52. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: An open-label study
53. Dietary supplementation with fish oil in ulcerative colitis
54. Treatment of ulcerative colitis with fish oil supplementation: A prospective 12 month randomised controlled trial
55. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease - A randomized, placebo-controlled, double-blind cross-over trial
56. Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study
57. Comparison of omega-3 fatty acids and sulfasalazine in ulcerative colitis
58. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
59. Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial
60. Paradoxical response to heparin in 10 patients with ulcerative colitis
61. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease
62. Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases
63. Low molecular weight heparin as adjuvant therapy in active ulcerative colitis
64. Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis
65. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease
66. Immunoregulatory role of interleukin 10 in patients with inflammatory, bowel disease
67. The prognosis of idiopathic proctitis
68. Progression of ulcerative proctosigmoiditis: Incidence and factors influencing progression
69. Clinical outcome of the first ten years of ulcerative colitis and proctitis
70. The natural history of ulcerative proctitis: A multicenter, retrospective study
71. Changes in extent of ulcerative colitis: A study on the course and prognostic factors
72. Ulcerative colitis and colorectal cancer. A population-based study
73. Colorectal cancer in ulcerative colitis: A cohort study of primary, referrals from three centres
74. The risk of colorectal cancer in ulcerative colitis; An epidemiologic study